SIMBOSPROST: Prevalence of metabolic syndrome and osteoporosis in prostate cancer patients treated with radiotherapy and androgen deprivation therapy: A multicentre, cross-sectional study

Ots, P.M. Samper; García, Julia Luisa Muñoz; Kavadoy, Y. Ríos; Paniagua, M.L. Couselo; Iturre, E. Villafranca; Liñán, M. Rodríguez; Casas, Ana; Soria, Rodrigo; Martínez, B. Ludeña; Torrecilla, J. López; Giner, M. Casaña; Laborda, Almudena Zapatero; García-Salazar, Ma Magdalena Márquez

doi:10.1016/j.rpor.2015.06.004

Cited by 7 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…50 Male hypogonadism is an independent risk factor for metabolic syndrome, while low testosterone and SHBG levels can predict metabolic syndrome in men. 51,52 Additionally, as mentioned above, ADT causes a high degree of alteration in the metabolic parameters and thus it is possible that ADT increases the risk of metabolic syndrome. Indeed, some studies have shown that about 36-55% of men receiving ADT for more than a year will develop metabolic syndrome, independent of age, race, and stage of PCa.…”

Section: 49mentioning

confidence: 98%

Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications

Tzortzis

Samarinas

Zachos

et al. 2017

View full text Add to dashboard Cite

Prostate cancer is the most common cancer among men and androgen deprivation therapy (ADT) is the most effective treatment for this disease. The cornerstone of the treatment of prostate cancer is inhibition of testosterone production which interrupts testosterone-induced growth of the prostate tumor. The dramatic decrease in testosterone levels, however, has several undesirable effects on the metabolic profile and bone metabolism and can also lead to fatigue, loss of libido, gynecomastia, and anemia, provoke vasomotor flushing, and generally affect the quality of life. Due to the long-term survival rates of patients with prostate cancer, treatmentrelated adverse effects are highly relevant and thus, in each clinical setting, the benefits of ADT must be weighed against treatment-related adverse effects. The current review focuses on the more recently described metabolic complications of androgen deprivation therapy, including obesity, diabetes, lipid alterations, metabolic syndrome, and cardiovascular disease. In addition, it provides practical management recommendations drawn from the available guidelines issued

show abstract

Section: 49mentioning

confidence: 98%

Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications

Tzortzis

Samarinas

Zachos

et al. 2017

View full text Add to dashboard Cite

show abstract

“…A US study of 2290 patients with prostate cancer found that only 197 (8.6%) underwent DXA scanning within one year before, and six months after starting ADT [ 17 ]. A smaller Spanish study found that 62% (168/270) of patients on ADT underwent DXA scanning [ 32 ]. The high level of DXA testing at our centre may have been due to the efforts of a small group of clinicians with heightened awareness of the deleterious effects of ADT on bone health in the setting of accessible DXA scanning.…”

Section: Discussionmentioning

confidence: 99%

Bone health assessment with dual energy X-ray absorptiometry in men with high-risk prostate carcinoma commencing adjuvant androgen deprivation therapy

Pan

Aherne

Shakespeare

et al. 2022

Rep Pract Oncol Radiother.

View full text Add to dashboard Cite

show abstract

“…Prostate cancer patients treated with radiotherapy combined with adjuvant hormonal therapy, regardless of the length of treatment, are twice more likely to be diagnosed with the metabolic syndrome than patients treated with radiotherapy alone [10].…”

Section: Metabolic Complications Of Hormonal Therapymentioning

confidence: 99%

Systemic complications in the hormonal treatment of prostate and breast cancer

Jagielska

Poniatowska²,

Tałasiewicz³

et al. 2017

Nowotwory. Journal of Oncology

View full text Add to dashboard Cite

Oncological treatment is often associated with a wide range of adverse effects. The article focuses on systemic complications that may occur during the hormonal therapy of prostate and breast cancer. Considering that current treatments are increasingly effective, the number of patients suffering from early and remote complications of cancer therapy can be expected to rise. Many undergo radical treatment and in this group in particular, close attention should be paid to the prevention, early diagnosis, and treatment of adverse effects. Hormonal disorders and their complications considerably affect the quality of life and life expectancy by upsetting general systemic homeostasis. NOWOTWORY J Oncol 2017; 67, 3: 206-214

show abstract

SIMBOSPROST: Prevalence of metabolic syndrome and osteoporosis in prostate cancer patients treated with radiotherapy and androgen deprivation therapy: A multicentre, cross-sectional study

Cited by 7 publications

References 33 publications

Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications

Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications

Bone health assessment with dual energy X-ray absorptiometry in men with high-risk prostate carcinoma commencing adjuvant androgen deprivation therapy

Systemic complications in the hormonal treatment of prostate and breast cancer

Contact Info

Product

Resources

About